McKesson (MCK) Gains 4.6% After Rival Cencora Files Earnings
As seen on the 24/7 Wall St. homepage on November 4, 2026.
A 4.57% jump to $1,065.70 adds roughly $5 billion to this $124 billion distributor, and it comes after Cencora, a competitor, filed Q4 earnings. McKesson has followed 3 of the last 4 Cencora reports with an average 4.4% move.
Continue ReadingShow less
McKesson finished at $1,065.70, up roughly 4.6%, one of the more consequential single-day swings in the drug distribution sector.
A quarterly earnings filing from Cencora, one of McKesson's closest competitors in pharmaceutical distribution, drove the move. McKesson has followed three of the last four Cencora earnings reports with an average move of 4.4%, and today's gain lands in line with that pattern.
Sponsored
The two companies operate in the same supply chain, serve many of the same pharmacy and health system customers, and face the same pricing and volume dynamics. When Cencora's results signal something about the health of drug distribution demand, the market reprices McKesson in the same direction almost immediately.
A 4.4% average move across four competitor earnings cycles is an unusually repeatable signal for a stock trading above $1,000, and today's session suggests the market sees no reason to break from it.